Allyson leverages her in-house experience to provide holistic counsel to publicly traded and late-stage private companies on corporate and securities law matters.
Allyson advises companies on SEC reporting and disclosure requirements, corporate governance, stock exchange requirements and proxy advisory firm policies. Allyson routinely represents issuers on a variety of transactions, with a focus on initial public offerings, follow-on offerings, private investments in public equity (PIPEs), registered direct offerings and mergers and acquisitions.
Before rejoining Mintz, Allyson was Senior Counsel, Corporate and Securities at a prominent tech company in New York, where she advised the board and senior management on a wide range of corporate and securities law matters.
Experience
Select Initial Public Offering Representations
- Viela Bio, Inc. in its $150 million initial public offering.
- NuCana plc. in its $114 million initial public offering.
- Quanterix Corporation in its $73.7 million initial public offering.
Select Follow-on Offering and Alternate Transaction Representations
- Intra-Cellular Therapies, Inc. in multiple offerings, including its $350 million follow-on offering, its $295 million follow-on offering, and its $150 million follow-on offering.
- Albireo Pharma, Inc. in multiple offerings, including its $160 million follow-on offering and its $65 million follow-on offering.
- Viela Bio, Inc. in multiple offerings, including its $170 million follow-on offering.
- Nucana plc. in multiple offerings, including its $70 million follow-on offering.
- J.P. Morgan, SVB Leerink, and Cowen in Acceleron Pharma Inc.’s $493 million follow-on offering.
- Goldman Sachs, Morgan Stanley, J.P. Morgan, and Cowen in GW Pharmaceuticals plc.’s $345 million follow-on offering.
- Goldman Sachs and Leerink Partners in a $50.5 million secondary offering of Achillion Pharmaceuticals, Inc.’s common stock by selling stockholder Johnson & Johnson Innovation-JJDC, Inc.
- Leerink Partners in ArQule, Inc.’s $65 million follow-on offering.
Select Mergers and Acquisitions Representations
- Albireo Pharma, Inc. in its reverse merger with Biodel Inc.
- F-star Therapeutics, Inc. in its reverse merger with Spring Bank Pharmaceuticals.
viewpoints
Reminder – T-1 Settlement Starts Today, Tuesday, May 28, 2024
May 28, 2024 | Alert | By Daniel T. Kajunski, Allyson Wilkinson
Starting today, Tuesday, May 28, 2024, the amendments to Securities Exchange Act Rule 15c6-1 take effect, shortening the settlement cycle for most broker-dealer securities transactions to the trade date plus one business day (T+1) from the trade date plus two business days (T+2). In this alert, we discuss the T+1 settlement cycle and best practices for issuers to mitigate compliance issues and reduce the risk of failed settlements.
News & Press
Events & Speaking
Recognition & Awards
Richard Mintz Scholarship Recipient
Boston College Law School’s Pro Bono Excellence Recognition
National Black Lawyers: Top 40 Under 40 (2022)
Massachusetts Lawyers Weekly: Excellence in the Law, Up & Coming Lawyer Award (2020)
Involvement
- Director, The Equity in Heart Transplant Project (2022 – present)
- Clerk, The Equity in Heart Transplant Project (2022 – 2023)
- Treasurer, Massachusetts Black Lawyers Association (2022 – 2023)
- Business Transactions Liaison, New Lawyers Steering Committee of the Boston Bar Association (2020 – 2021)
- Director, Boston College Law School Black Alumni Network (2019 – 2020)
Recent Insights
Reminder – T-1 Settlement Starts Today, Tuesday, May 28, 2024
May 28, 2024| Alert|
